Prospective study of *Candida auris* nucleic-acids in wastewater solids in 190 wastewater treatment plants in the United States suggests widespread occurrence

Alessandro Zulli[1], Elana M. G. Chan[1], Bridgette Shelden[2], Dorothea Duong[2], Xiang-Ru S. Xu[2], Bradley J. White[2], Marlene K. Wolfe[3], Alexandria B. Boehm[1*]

1. Department of Civil and Environmental Engineering, Stanford University, 473 Via Ortega, Stanford, California, 94305
2. Verily Life Sciences LLC, South San Francisco, CA, USA
3. Gangarosa Department of Environmental Health, Rollins School of Public Health, Emory University, 1518 Clifton Rd, Atlanta, GA, USA, 30322

* Corresponding author: aboehm@stanford.edu

Abstract

Candida auris is an emerging, multidrug-resistant fungal pathogen that poses a significant public health threat in healthcare settings. Despite yearly clinical cases rapidly increasing from 77 to 8,131 in the last decade, surveillance data on its distribution and prevalence remains limited. We implemented a novel assay for *C. auris* detection on a nationwide scale prospectively from September 2023 to March 2024, analyzing a total of 13,842 samples from 190 wastewater treatment plants across 41 U.S. states. Assays were extensively validated through comparison to other known assays and internal controls. Of these 190 wastewater treatment plants, *C. auris* was detected in the wastewater solids of 65 of them (34.2%) with 1.45% of all samples having detectable levels of *C. auris*. Detections varied seasonally, with 2.00% of samples positive in autumn versus 1.01% in winter ($p<0.0001$). The frequency of detection in wastewater was significantly associated with states having older populations ($p<0.001$), sewersheds containing more hospitals ($p<0.0001$), and sewersheds containing more nursing homes ($p<0.001$). These associations are in agreement with known *C. auris* epidemiology. This nationwide study demonstrates the viability of wastewater surveillance for *C. auris* surveillance, and further highlights the value of wastewater surveillance when clinical testing is constrained.

Introduction

Healthcare associated infections are rapidly emerging as a global public health threat due to increasing levels of antimicrobial resistance and an aging worldwide population (1–3). Among these infections, *Candida auris,* first identified in 2009 in Japan, is an opportunistic, drug-resistant fungal pathogen with significant levels of associated morbidity and mortality (3–6). It has now spread to over 40 countries and has been designated as a priority pathogen by both international organizations, such as the World Health Organization (WHO), and national organizations, such as the Center for Disease Control and Prevention (CDC) in the United States, where it is now a nationally notifiable condition (4, 6, 7). The estimated crude mortality rate within the United States for *C. auris* infections was 34% between 2017-2022 (5).

47

48 *C. auris* prevention and control efforts are exacerbated by the fungus' hardiness on fomites and
49 high levels of transmissibility (6–8). The fungus has been found to persist for at least 7 days on
50 both moist and dry surfaces, increasing the frequency and chance of transmission events in
51 healthcare settings (9, 10). Of particular concern are high-touch plastic surfaces within
52 healthcare facilities where *C. auris* was found to be viable for up to 14 days (10). In addition, *C.*
53 *auris* is resistant to many common disinfectants so proper decontamination protocols are
54 difficult and time intensive in already strained healthcare facilities (11). Further complicating
55 containment efforts are the different presentations in colonized individuals compared to those
56 with acute infections, with most colonized individuals presenting as asymptomatic (4). A lack of
57 screening in high-risk patients and misidentification of specimens as other *Candida* subspecies
58 has also contributed to the rapid spread of *C. auris* (5, 12). In the United States, clinical cases
59 rose from 77 between 2013-2016 to 8,131 in 2022 and are projected to continue rising (5, 13).
60

61 Despite this tremendous increase in cases and the accompanying screening efforts, clinically
62 available data are still sparse, with many institutions not speciating *Candida* cases resulting in
63 underreporting cases in long-term care facilities and nursing homes (13, 14). Many of these
64 facilities do not have the necessary equipment or human capital to implement speciation efforts
65 and screening, which has been shown to be a necessary part of successful containment efforts
66 (12). Alternative approaches to clinical surveillance are therefore necessary to better track both
67 the spread and severity of outbreaks. Wastewater represents a naturally composite sample
68 which is particularly useful for disease surveillance as it contains urine, feces, vomit, saliva,
69 sloughed skin cells, sputum, and other excretions. Wastewater surveillance has been
70 successfully used to track a wide variety of human pathogens including enterovirus, SARS-CoV-
71 2, influenza A virus, and flavivirus (15–17). Like these viruses, *C. auris* has been detected in
72 urine and stool samples from colonized or infected individuals, though it is typically diagnosed

through presence in the blood or dermis of infected patients (4, 10, 18). Furthermore, recent studies have demonstrated the persistence and subsequent detection of *C. auris* in wastewater samples in Nevada and Florida (19). Early detection of this emerging pathogen through environmental surveillance may complement clinical surveillance efforts and inform containment and screening procedures (20).

In this paper, we present the results of a United States-wide wastewater monitoring effort for *C. auris* and compare the data to publicly available, recent, clinical case data. We also compare results to available demographic indicators and healthcare facility locations. Detections of *C. auris* in wastewater demonstrate wide geographical occurrence , and we demonstrate that these wastewater detections appear to be associated with age and presence of hospitals and nursing homes in adjacent communities. These results demonstrate the advantages of using wastewater surveillance for the detection of emerging pathogens and for supplementing clinical testing efforts.

Methods

RT-PCR assays. We designed a novel probe for *Candida auris* to use in conjunction with previously published specific and sensitive forward and reverse primers (21). The assay targets the region of the genome encoding the 5.8S ribosomal RNA, all of ITS2, and a fragment of 28S ribosomal RNA. To design the probe, *C. auris* genome sequences were downloaded from the National Center for Biotechnology Information (NCBI) and aligned to identify conserved regions located between the primers. The probe was designed *in silico* using Primer3Plus (https://primer3plus.com/). Parameters used in the design process (e.g., sequence length, GC content, and melt temperatures) are provided in Table S1. The primers and probe were then screened for specificity *in silico* by blasting the sequences in NCBI and *in vitro* against fungal

99 panels, or cDNA sequences. The *in silico* analysis was performed by excluding all *C. auris*
100 genomes from a BLAST search, thereby only giving off-target matches (22).
101
102 The primers and probe were tested *in vitro* for specificity and sensitivity using a fungal panel
103 (NATCTVPOS-BD, Zeptomatrix Buffalo, NY) and *Candida auris* Satoh et Makimura (ATCC
104 MYA-5001) purchased from American Type Culture Collection (ATCC, Manassas, VA). The
105 fungal panel NATCTVPOS-BD includes chemically inactivated *Candida albicans*, *C. krusei*, *C.*
106 *glabrata*, and *Trichomoniasis vaginalis*. Nucleic acids were extracted from fungi using Chemagic
107 Viral DNA/RNA 300 Kit H96 for Chemagic 360 (PerkinElmer, Waltham, MA).
108
109 Nucleic acids were used undiluted as template in digital droplet RT-PCR (ddRT-PCR) singleton
110 assays for sensitivity and specificity testing in single wells. The concentration of targets used in
111 the *in vitro* specificity testing was between 10^3 and 10^4 copies per well. Negative RT-PCR
112 controls were included on each plate.
113
114 We used an RT-PCR assay for the in vitro sensitivity and specificity testing as the goal was to
115 ultimately multiplex the *C. auris* assay in a panel that includes RNA-genome viruses. The
116 implications of the use of RT-PCR, and a comparison to results obtained using PCR are further
117 investigated, as described below. Regardless, this means the assay detects both DNA and RNA
118 targets.
119
120 **Clinical surveillance data.** The National Notifiable Disease Surveillance System (NNDSS) is a
121 nationwide collaboration to which all levels of healthcare providers share health information
122 about nationally notifiable infectious and noninfectious diseases (23). Case reports are compiled
123 on a weekly basis using uniform case definitions from 50 states, the District of Columbia, New
124 York City, and 5 territories (American Samoa, Guam, Northern Mariana Islands, Puerto Rico,

125 U.S. Virgin Islands) (23). For this study, we used publicly available information on NNDSS for
126 *Candida auris* from 11 September 2023 to 1 March 2024 (https://data.cdc.gov/api/views/x9gk-
127 5huc/rows.csv?accessType=DOWNLOAD). Dates of case determination varied but included the
128 following in order of preference: date of disease start, date of diagnosis, date of laboratory
129 result, date of first report to public health system, or date of state report (24). States which did
130 not report clinical case data were omitted from analyses. It should be noted that this database is
131 known to be incomplete as many local jurisdictions do not submit data; additional data on C.
132 auris cases or Candida cases may be available from other local or regional sources that are not
133 publicly available or currently updated.
134
135 **Wastewater data**: **sample collection.** Wastewater measurements were made prospectively as
136 part of a wastewater surveillance program. Between 11 September 2023 and 1 March 2024,
137 wastewater samples (either 24-hour composited influent or grab samples from the primary
138 clarifier, Table S1) were collected by wastewater treatment plant (WWTP) staff using sterile
139 containers. Samples were typically obtained approximately three times per week and shipped
140 overnight to the laboratory at 4°C where they were processed immediately with no storage.
141 Samples were collected from 190 distinct WWTPs across a total of 41 states over the course of
142 the study period (Figure 1). A total of 13,842 samples were collected and analyzed as part of
143 this study.
144
145 **Wastewater data**: **pre-analytical processing.** *C. auris* is expected to be associated with the
146 solid phase of wastewater based on previous empirical measurements across liquid and solid
147 phases in wastewater and its size (diameter = 2.5-5 μm), so in this study we made
148 measurements in the solid phase of wastewater (25, 26). Details of the isolation of solids from
149 the samples are provided in other peer-reviewed publications (27). In short, samples were
150 centrifuged to dewater the solids. One aliquot of dewatered solids was used for nucleic-acid

151 extractions and another was used to determine the dry weight of the solids using an oven (27).
152 Approximately 75 mg of dewatered solids was added per milliliter of DNA/RNA shield (Zymo,
153 Irvine, CA) spiked with bovine coronavirus vaccine as a positive extraction control. This mixture
154 of solids and buffer was previously shown to have minimal inhibition.(28) The mixture was
155 homogenized after the addition of grinding balls, and centrifuged; the supernatant was used
156 immediately for nucleic-acid extractions. Nucleic-acids were extracted from 6-10 replicate
157 aliquots of the supernatant using the Chemagic Viral DNA/RNA 300 kit H96 for the Perkin Elmer
158 Chemagic 360 (Perkin Elmer, Waltham, MA) followed by PCR inhibitor removal with the Zymo
159 OneStep-96 PCR Inhibitor Removal kit (Zymo Research, Irvine, CA). Whether 6 or 10 replicates
160 were used is specified in Table S1. The suspension volume entered into the nucleic-acid
161 extraction process was 300 µl and 50 µl of nucleic-acids were retrieved after the inhibitor
162 removal kit. Negative extraction controls consisted of BCoV-vaccine spiked DNA/RNA Shield.
163 Nucleic-acids were used immediately as template in PCR as described next, with no storage.
164
165 **Wastewater data**: **analytical processing.** We used droplet digital reverse transcription
166 polymerase chain reaction (ddRT-PCR) to measure nucleic-acids in wastewater. We measured
167 pepper mild mottle virus (PMMoV) as an endogenous positive control as concentrations tend to
168 be extremely elevated in wastewater samples; we measured BCoV as an endogenous, spiked-
169 in control (28–30). Methods applied to wastewater solids to measure PMMoV and BCoV in a
170 duplex reaction are provided in detail elsewhere (27). The *C. auris* assay (Table 1) was run in
171 multiplex using a probe-mixing approach. The exact assays that *C. auris* was multiplexed with
172 varied slightly over the duration of the project for some of the plants (information is provided in
173 Table S2). Multiplexing *C. auris* with these targets did not affect *C. auris* quantification (see SI
174 Figure S1). The results from those other assays are not provided herein. The PMMoV/BCoV
175 duplex and *C. auris* multiplex assays were run on 96-well plates. Each 96-well PCR plate of
176 wastewater samples included PCR positive controls for each target assayed on the plate in 1

177 well, PCR negative no template controls in two wells, and extraction negative controls in two
178 wells. PCR positive controls consisted of *C. auris* DNA. Each of the 6 or 10 replicate nucleic-
179 acid extracts were run in their own wells to measure *C. auris*. Two randomly selected or 10
180 replicate nucleic-acid extracts were run in their own wells to measure PMMoV and BCoV (Table
181 S1).
182
183 Table 1. Primers and probes used in this study for detection of *C. auris* nucleic acids. Primers
184 and probes were purchased from Integrated DNA Technologies (Coralville, IA, USA). The
185 probes contained fluorescent molecule HEX and quenchers (5′ HEX/ZEN/3′ IBFQ); HEX,
186 hexachloro-fluorescein; ZEN, a proprietary internal quencher from Integrated DNA Technologies
187 (Coralville, IA, USA); and IBFQ, Iowa Black FQ. Amplicon size is 163 basepairs.
188

Forward	CGCACATTGCGCCTTGGGGTA
Reverse	GTAGTCCTACCTGATTTGAGGCGAC
Probe	CTTCTCACCAATCTTCGCGGT

189
190
191 ddRT-PCR was performed on 20-µl samples from a 22 µl-reaction volume, prepared using 5.5
192 µl of template mixed with 5.5 µl of One-Step RT-ddPCR Advanced Kit for Probes (Bio-Rad
193 1863021), 2.2 µl of 200 U/µl Reverse Transcriptase, 1.1 µl of 300 mM dithiothreitol (DTT), and
194 primers and probes mixtures at a final concentration of 900 nM and 250 nM, respectively.
195 Primer and probes for assays were purchased from Integrated DNA Technologies (IDT, San
196 Diego, CA) (Table 1). *C. auris* was measured in reactions with undiluted template whereas
197 PMMoV and BCoV were run on template diluted 1:100 in molecular grade water. It is important
198 to note that an RT step was used because during the prospective study, we were measuring a
199 large number of RNA genome viruses. Therefore, the *C. auris* target quantified should be
200 interpreted as copies of RNA plus DNA.
201
202 Droplets were generated using the AutoDG Automated Droplet Generator (Bio-Rad, Hercules,
203 CA). PCR was performed using Mastercycler Pro (Eppendforf, Enfield, CT) with with the

204 following cycling conditions: reverse transcription at 50°C for 60 minutes, enzyme activation at
205 95°C for 5 minutes, 40 cycles of denaturation at 95°C for 30 seconds and annealing and
206 extension at 59°C (for *C. auris*) or 56°C (for PMMoV and BCoV) for 30 seconds, enzyme
207 deactivation at 98°C for 10 minutes then an indefinite hold at 4°C. The ramp rate for
208 temperature changes were set to 2°C/second and the final hold at 4°C was performed for a
209 minimum of 30 minutes to allow the droplets to stabilize. Droplets were analyzed using the
210 QX200 or the QX600 Droplet Reader (Bio-Rad). A well had to have over 10,000 droplets for
211 inclusion in the analysis. All liquid transfers were performed using the Agilent Bravo (Agilent
212 Technologies, Santa Clara, CA).
213
214 Thresholding was done using QuantaSoft™ Analysis Pro Software (Bio-Rad, version 1.0.596)
215 and QX Manager Software (Bio-Rad, version 2.0). Replicate wells were merged for analysis of
216 each sample. In order for a sample to be recorded as positive, it had to have at least 3 positive
217 droplets. Concentrations of RNA targets were converted to concentrations in units of copies
218 (cp)/g dry weight using dimensional analysis. The total error is reported as standard deviations.
219 Three positive droplets across 6 merged wells corresponds to a concentration between ~1000
220 cp/g; the range in values is a result of the range in the equivalent mass of dry solids added to
221 the wells. Data collected as part of the study are available from the Stanford Digital Repository
222 (https://purl.stanford.edu/hv291tt0888).
223
224 **Wastewater: Confirmatory analyses.** We selected seven samples (Table S3) with relatively
225 high concentrations of *C. auris,* as measured above, to test another published *C. auris* assay by
226 Barber et al. (25) for detecting *C. auris* in wastewater. The assay used by Barber et al. targets
227 the same region of the *C. auris* genome as the assay in Table 1 but uses different primers and
228 probes (Table S4) (25). Archived nucleic acid extracts, stored at -80°C, from those samples
229 were thawed and then run as template using the Barber et al. assay as well as the assay

230 described herein (Table 1). The samples were run in duplex with an assay that targets the N
231 gene of SARS-CoV-2 (28). *C. auris* was run using a probe labeled with fluorescein amidite
232 (FAM). The methods described above for the analytical procedures (number of replicate wells,
233 negative and positive controls) were used.
234
235 These same seven samples were assayed with and without the reverse transcription step.
236 Nucleic-acid extracts were thawed and run exactly as described for the prospective study
237 except that the RT and DTT were not added to the mastermix.
238
239 We selected a subset of five of the seven samples (Table S3) for Sanger sequencing of the
240 PCR amplicon. One µl of archived (at -80°C) nucleic acid extracts was used as the template in a
241 50-µl PCR reaction prepared according to manufacturer's protocol with Q5® High-Fidelity 2X
242 Master Mix (New England Biolabs, Ipswich, MA) using the primers in Table 2. The thermocycler
243 program was run at an annealing temperature of 67°C for 30 seconds and extension at 72°C for
244 30 seconds. *C. auris* DNA was used as a positive control. PCR products were run on a 2%
245 agarose gel stained with SYBR Safe gel stain (Thermofisher, Fremont, CA) and amplicons of
246 the expected size (259 bp) were excised and gel purified using Zymo gel DNA recovery kit
247 (Irvine, CA). The purified DNA was then sent to Molecular Cloning Laboratories (South San
248 Francisco, CA) for sanger sequencing. Sequences were downloaded and aligned with *C. auris*
249 genomes using Snapgene software.
250
251
252



Figure 1. Location of wastewater treatment plants (WWTPs) with *Candida auris* DNA data included in the paper. Each blue dot represents the location of a WWTP.

Demographic data. *C. auris* hospitalizations are most common among older adults (5). We used 5-year estimates from the 2022 American Community Survey (ACS) at the state level to identify the median age of states with participating WWTPs (n = 41 states) (31).

Hospitals and nursing homes data. *C. auris* is particularly a concern in hospitals and nursing homes (5, 14, 20). We obtained the locations of hospitals and nursing homes in the United States from the US Department of Homeland Security's Homeland Infrastructure Foundation-Level Data (HIFLD) database (https://gii.dhs.gov/HIFLD) (32, 33). We selected all types of hospitals and nursing homes with an "open" status and then determined the number of hospitals and nursing homes in each sewershed using the Tabulate Intersection geoprocessing tool in ArcGIS Pro (version 3.1.1). Sewershed boundaries were provided by most WWTPs (n = 115).

268 For WWTPs that did not provide a sewershed (n = 75), we approximated sewershed boundaries
269 based on the zip codes serviced by the WWTP and USA ZIP Code Boundaries geospatial data
270 set published by Esri (Source: TomTom, US Postal Service, Esri) (34).
271
272 **Data analysis.** We made comparisons on the basis of percent of positive detections in
273 wastewater. Percentage of positive detections of *C. auris* was calculated by counting all positive
274 observations for a single WWTP and dividing by the total number of observations. Wastewater
275 measurements in each state were aggregated by Morbidity and Mortality Weekly Report
276 (MMWR) week, and we calculated the percentage of wastewater measurements that were
277 positive for *C. auris* each week.
278
279 Spearman's rank correlation coefficients were used to assess the association between weekly
280 (MMWR weeks) publicly available NNDSS clinical data and wastewater percent positive
281 detections (hereafter "detections") of *C. auris* for each state (n=18 states with wastewater and
282 clinical data). Case data from NNDSS, available on a weekly basis for each state, was used
283 after adjusting for population (cases per million people, Fig 2a).
284
285 We tested whether concentrations measured by the assay presented in Table 1 were different
286 from those measured by the Barber et al. assay using RT-ddPCR on 9 representative samples
287 (Table S3, Figure S2) (25). We ran the same samples using RT-ddPCR and ddPCR with no RT
288 step (Table S3, Figure S2). Differences between these controls were assessed using a paired t-
289 test.
290
291 We also assessed the relationship between *C. auris* percent positive detections and several
292 other contextual and demographic factors. We explored seasonality by assessing *C. auris*
293 detections in wastewater samples collected in fall (defined as Sept 1 to Nov 30) and winter

294 (defined as Dec 1 to Feb 29). We then assessed the association between *C. auris* detections
295 and age at the state level. We grouped WWTPs by those in states with a median age less than
296 versus greater than or equal to the national median age (39 years) (31). Lastly, we assessed
297 the association between *C. auris* detections and hospitals and nursing homes at the sewershed
298 level. We grouped WWTPs by those with a sewershed intersecting (1) less than versus greater
299 than or equal to the median number of hospitals among all sewersheds (median: 1 hospital) and
300 (2) less than versus greater than or equal to the median number of nursing homes among all
301 sewersheds (median: 7 nursing homes). For seasonality, we compared the percentage of
302 wastewater samples positive for *C. auris* in each season. For age, hospitals, and nursing
303 homes, we compared the percentage of wastewater samples that were positive for *C. auris*
304 across WWTPs in the less than median group versus the greater than or equal to median group.
305 The null hypothesis tested for each of these variables was that there were no differences
306 between the two groups.
307
308 Statistical significance and 95% confidence intervals between the groups described above were
309 assessed through bootstrapping (35, 36). For each variable and group, a distribution of values
310 was generated through random sampling with replacement 10,000 times. Significance was then
311 calculated using the proportion of values below our calculated statistic (i.e. whether the
312 calculated statistics were above the 95% confidence intervals). This same method was used
313 when assessing differences between assays (Fig S2) and seasonal differences in detection. In
314 those cases, grouping was done based on assay and season, respectively.
315
316 **Results**
317
318 **QA/QC.** The *C. auris* assay was found to be sensitive and specific. The *in silico* analysis
319 indicated no primer or probe sequence was more than an 85% match to off-target matches, and

320 there was no overlap found between combinations of forward primer off-targets, reverse primer
321 off-targets, and probe off-targets. These factors indicate a high level of specificity in the primer-
322 probe combination used. The in vitro testing confirmed sensitivity and specificity of the *C. auris*
323 assay as *C. auris* nucleic-acids were positive and the remaining non-target nucleic-acids were
324 negative.
325
326 Results are reported following the Environmental Microbiology Minimal Information (EMMI)
327 guidelines (see SI and Figure S3).(37) All positive and negative controls performed as expected,
328 indicating acceptable assay performance. Median (IQR) BCoV recoveries across all wastewater
329 samples were 1.08 (0.82, 1.43) indicating good recovery across all samples. Recoveries
330 exceeding 1 are the result of uncertainties in the measurement of BCoV added to the buffer
331 matrix. PMMoV levels were elevated in all samples indicating lack of gross extraction failures
332 (median = 4.8×10^{8} cp/g, min = 5.0×10^{5} cp/g, max = 2.02×10^{11} cp/g).
333
334 As a further validation step, *C. auris* was quantified in a subset of samples also using the Barber
335 et al. assay (Figure S2) (25). Concentrations measured by the two assays closely matched, with
336 no statistically significant differences ($p>0.05$). Comparisons between concentrations measured
337 using RT-ddPCR and ddPCR showed similar results (Figure S2); no significant differences were
338 found ($p>0.05$). Additionally, the PCR amplicons obtained using the forward and reverse
339 primers were sequenced and the sequences matched the *C. auris* genome segment targeted
340 (Figure S4).
341
342 **National Overview**. The study period spanned 11 September 2023 to 1 March 2024.
343 Wastewater data were available from 190 distinct WWTPs in 41 states (Table S1). The number
344 of WWTPs in these states ranged between 1–57 WWTPs (median: 2 WWTPs), with population
345 coverage of the sewersheds ranging from 0.13% to 59.5% of the population of each individual

346 state (median: 5.75%). The number of wastewater samples collected and analyzed from
347 individual WWTPs ranged between 23–173 samples (median: 72 samples) during the study
348 period. In total, 13,842 wastewater samples were collected and analyzed across all WWTPs
349 during the study period. *C. auris* concentrations in these samples ranged from below the limit of
350 detection to 1,456,751 cp/g, with 1.45% (n = 200 samples) of samples above the lowest
351 detectable concentration. Sixty five (34.21%) WWTPs across 26 states had at least one
352 detectable *C. auris* concentration during the study period, and the percentage of positive
353 samples from these WWTPs ranged between 0.58%–46.48% (median: 1.49%). Time series
354 heatmaps of *C. auris* detections at each of the 190 WWTPs are provided in Figure S5.
355 Seasonally, 2.00% (n=6754) of observations were positive during autumn (defined as Sep 1 to
356 Nov 30), and 1.01%(n=7245) of observations were positive during winter (defined as Dec 1 to
357 Feb 29). This difference was statistically significant when assessed by a bootstrapping
358 approach ($p<0.0001$).
359
360 Clinical data from the National Notifiable Disease Surveillance System (NNDSS) were
361 downloaded for comparison to wastewater data, and no significant correlations were found
362 between wastewater detections and population adjusted clinical case rates (Spearman's rho
363 between -0.10 and 0.23 for the 18 states, all $p>0.05$). Several states had obvious divergence
364 between wastewater positivity rates and population adjusted NNDSS clinical case rates (**Figure**
365 **2)**. For example, in Maine, 13.3% of wastewater samples were positive for *C. auris* despite not
366 reporting any clinical cases during the study period to NNDSS (**Figure 2**). Twelve states which
367 did not report *C. auris* cases to the NNDSS were found to have positive detections of *C. auris*.
368 **Figure 3** shows percentage positive detections as a function of population normalized clinical
369 cases and highlights the limited clinical data available.
370



Figure 2: Map showing percentage of positive wastewater samples and population normalized case numbers from NNDSS across the United States. **Figure 2a** shows the normalized number of cases per million in each state as reported to NNDSS during the study period. **Figure 2b** shows the percentage of positive wastewater samples in each of the states surveilled during the study period. Yellow represents low normalized values while black represents high normalized values. Gray states represent areas without available data.



Figure 3. Comparison of wastewater percent positive detections and total clinical cases as reported by NNDSS. Only states with clinical data reported to NNDSS are included. Each labeled point represents the percentage of positive wastewater samples in that state and the number of cases reported to NNDSS. The state abbreviation is above each data point.

Population demographics and healthcare facility locations and *Candida auris.*

WWTPs were grouped using three separate statistics: median age of the state, number of hospitals in the sewershed, and number of nursing homes in the sewershed (Fig 4). The median age in the United States is 39 years as of the latest American Community Survey (ACS) data (31). Seventy-eight WWTPs were located in a state with a median age at or above the national median age; 112 WWTPs were located in a state with a median age below the national median age. As shown in **Figure 4a**, among WWTPs in states with a median age at or above the national median age, 2.03% (95% CI: [0.80-3.50]) of all wastewater samples were positive for *C. auris*. Among WWTPs in states with a median age below the national median age, 0.83% (95% CI: [0.34-1.38]) of all wastewater samples were positive for *C. auris*. This difference was statistically significant when assessed by bootstrapping ($p < 0.001$).

398 The median number of hospitals in the sewersheds was 1 hospital (range: 0–74 hospitals).
399 WWTPs were grouped by whether they contained 0 hospitals (fewer than the median, n = 54) or
400 1 or more hospitals in their sewersheds (equal to or greater than the median, n = 136). We
401 found that 1.78% (95% CI: [0.92-2.90], n = 10,019) of samples from WWTPs with at least 1
402 hospital in their sewersheds were positive for *C. auris* whereas 0.62% (95% CI: [0.34-1.11], n =
403 3,819) of samples from WWTPs with no hospital in their sewershed were positive for *C. auris*
404 (**Figure 4b**). This difference was significant when assessed by bootstrapping ($p < 0.0001$).
405
406 The median number of nursing homes in the 190 sewersheds was 7 (range: 0–420 nursing
407 homes). WWTPs were grouped by whether they contained 0–6 nursing homes (fewer than the
408 median, n = 91) or 7 or more nursing homes in their sewersheds (equal to or greater than the
409 median, n = 99). We found that 1.92% (95% CI: [0.89–3.46], n = 7,544) of samples from
410 WWTPs with 7 or more nursing homes in their sewersheds were positive for *C. auris* whereas
411 0.87% (95% CI: [0.47–1.47], n = 6,294) of samples from WWTPs with 0–7 nursing homes in
412 their sewersheds were positive for *C. auris* (**Figure 4c**). This difference was significant when
413 assessed by bootstrapping ($p < 0.001$).
414



Figure 4. Comparison of wastewater detections across different groups. *** indicates p<0.001, **** indicates p<0.0001. **Figure 4a** shows the percentage of positive samples for states at or above the median age compared to those below. **Figure 4b** shows the percentage of positive samples when grouped by number of hospitals at the sewershed level. **Figure 4c** shows the same statistic when grouped by number of nursing homes, again at the sewershed level. Error bars represent 95% confidence intervals derived from the bootstrapping approach.

423
424 **Discussion**

425

426 Previous studies at the sewershed scale have shown that detection of *C. auris* in wastewater is
427 indicative of ongoing outbreaks in the contributing population (19, 25). To our knowledge, this
428 study represents the first nationwide wastewater monitoring effort of *C. auris* and comparison to
429 national clinical case data (23). We first demonstrate the sensitivity and specificity of the assay
430 used in this study through comparisons to published assays, sequencing (Figure S2, S4), and in
431 silico analyses. The widespread detection of *C. auris* in wastewater suggests a significant gap in
432 clinical case data reported to the NNDSS. Indeed, it is known that many local jurisdictions do
433 not provide data for inclusion in NNDSS. We found that *C. auris* detections are more frequent in
434 states with older populations and in sewersheds with higher numbers of nursing homes and
435 hospitals. These findings are consistent with *C. auris* infections being more common in older,
436 more susceptible populations and further support the assertion that clinical case data may be
437 incomplete.

438

439 *C. auris* has gone from initial detection in the United States in 2013 to being declared an
440 "Urgent" and notifiable pathogen in 2019 by the United States (CDC) (14, 20, 38). The rate of
441 testing volume and clinical positives has rapidly increased, with 17 states identifying their first *C.*
442 *auris* cases between 2019 to 2021 (14). Despite this, clinical testing for *C. auris* is far from
443 ubiquitous and not conducted uniformly across the United States (14, 39). On-site PCR testing
444 of clinical specimens is rare, and samples often have to be sent to public health or reference
445 laboratories, further increasing the cost of testing and the turnaround time before the data
446 reaches public health officials (39). Detections of *C. auris* nucleic-acids in wastewater collected
447 throughout the United States demonstrate a need for increased clinical testing and reporting

448 capacity, and the capability of wastewater testing to serve as a sentinel surveillance mechanism
449 for emerging pathogens.
450
451 *C. auris* is an opportunistic pathogen that often infects the elderly and immunocompromised
452 within long-term healthcare facilities (10, 20, 40). Following our detection of *C. auris*, we
453 investigated potential demographics and healthcare facilities related to its pathology using data
454 from the ACS and US Department of Homeland Security's HIFLD database (31, 41). We
455 analyzed age, number of hospitals, and number of nursing homes as plausible factors impacting
456 the presence of *C. auris* within a sewershed or state. We found significant differences between
457 the percentage of positive detections of *C. auris* in states with a median age less than versus
458 greater than or equal to the national median age. Similarly, we found significant differences
459 between the percentage of positive detections of *C. auris* in sewersheds with less than versus
460 greater than or equal to the median number of hospitals and nursing homes. States with a
461 population above the national median age were more than three times as likely to detect *C.*
462 *auris* in a given wastewater sample. At the sewershed level, locations with 1 or more hospitals
463 had three times the amount of *C. auris* detections than locations with no hospitals. Similarly,
464 sewersheds with greater than or equal to the median number of nursing homes had over twice
465 as many detections of *C. auris* as those with fewer than the median number of nursing homes.
466 These findings are consistent with the known epidemiology of *C. auris*, as infected patients'
467 median age is 68 and outbreaks are prevalent in long-term healthcare facilities and nursing
468 homes (5, 14). The presence of an at-risk population appears to be strongly associated with *C.*
469 *auris* wastewater detections, suggesting public health efforts are appropriately focused on these
470 at-risk populations.
471
472 Significant steps were taken to ensure the validity of detection results. A similar assay was used
473 by Barber et al. for the detection of *C. auris* in southern Nevada during an outbreak (25). We

474 tested nine samples from three different states using both the assay presented in this study and
475 the one used by Barber et al. (25). No statistically significant difference was found between the
476 two assays, which both targeted the same region of an internally transcribed spacer region. Our
477 assay was further validated using a subset of 5 of these 9 samples through sequencing. The
478 amplicons generated by our forward and reverse primers independently and accurately matched
479 the reference amplicon, indicating specific amplification (Figure S4). Together, these results
480 demonstrate that the assay used in this study is highly specific. Finally, we used an RT-PCR
481 assay to detect *C. auris* which means the assay should detect both RNA and DNA. We
482 measured some samples using both RT-PCR and PCR and the results indicated that most of
483 the target nucleic acids in those samples were DNA. This was somewhat surprising since we
484 expect the DNA target (located in the region of the genome that encodes ribosomal RNA)
485 should be transcripted into RNA by *C. auris*. Future work will need to be done to further
486 investigate the relative proportion of target RNA versus DNA *C. auris* targets in wastewater.
487 Regardless, the use of an RT-PCR assay, allowing detection of both RNA and DNA, should
488 increase the sensitivity of the assay (by detecting both nucleic-acids) yet perhaps complicate
489 interpretation of measured concentrations. For this reason, we only use the data in
490 presence/absence format.
491
492 Overall, our results demonstrate that *C. auris* wastewater surveillance can provide timely
493 information on geographical distribution and help identify at-risk populations; wastewater data
494 can be available within 24-48 hours of sample collection. As an emerging disease, clinical
495 testing for *C. auris* largely depends on shipping samples to public health laboratories (7, 13, 14).
496 Wastewater surveillance can help fill this gap for municipalities and states without the capital to
497 fund testing systems, providing community level information as to the prevalence, and more
498 importantly, the spread of *C. auris*. These data are critical to public health responses,
499 particularly when dealing with pathogens that do not or did not have robust clinical testing

500 systems such as Dengue virus, SARS-CoV-2, and *C. auris* (14, 16, 17, 39). *C. auris* wastewater
501 surveillance data can then be used to implement stricter screening protocols, cleaning
502 protocols, and other non-pharmaceutical interventions that can prevent the spread of illness
503 amongst vulnerable populations (9, 10, 20).
504 There are limitations associated with this study. Importantly, the availability of clinical data was
505 limited due to the recent classification in 2018 of *C. auris* as a notifiable disease, making in-
506 depth analyses of associations between wastewater detections and clinical data on infections
507 unfeasible. In addition, it is well understood that the NNDSS database may not contain all the
508 information on C. auris positive cases in the United States; local jurisdictions may have local
509 data to inform public health response to infections and those data were not available for this
510 work. Local jurisdictions are encouraged to use these wastewater data to compare to their local
511 case rates. Further, wastewater sampling was not uniform across the United States or within
512 individual states, which could introduce biases into the analyses. Within the demographic data
513 available at the sewershed level, information was limited as to the size of nursing homes and
514 hospitals, which might be important factors controlling associations with wastewater data on *C.*
515 *auris.* Lastly, we were unable to link specific wastewater concentrations to population-level
516 incidence. Further experiments are necessary to understand the shedding patterns of *C. auris* in
517 human excretions as to provide this direct link to disease occurrence in the contributing
518 population. These experiments are particularly important to the determination of the significance
519 of wastewater detections, as *C. auris* contributions to wastewater could potentially be from
520 colonized individuals or individuals with acute infection. Finally, an additional limitation is that we
521 cannot rule out the potential for *C. auris* detections in wastewater to be from zoonotic or
522 environmental sources. Detections have been shown to match underlying expected
523 demographic indicators such as age and presence of nursing homes, further lending credence
524 to the source of detections being human. While there is no evidence to support the possibility of
525 zoonotic or environmental contributions of *C. auris* nucleic-acids to wastewater, further research

is needed to see if such evidence might exist. There have been case reports of *C. auris* infections in canines, and *Candida spp*. have been detected using culture and other molecular methods from biofilms in sewer pipes (42–45). It should be noted that wastewater detection of Candida auris collected at the wastewater treatment plant scale does not imply community-spread of the pathogen, but is consistent with its presence in one or more individuals within the sewershed.

Acknowledgements. We acknowledge all the wastewater treatment plant staff who provided samples for this project.

536
537
538
539 **References**
540

541 1. Ageing and health. https://www.who.int/news-room/fact-sheets/detail/ageing-and-health.
542 Retrieved 17 January 2024.
543 2. Hospital-Acquired Infections - ClinicalKey.
544 https://www.clinicalkey.com/#!/content/playContent/1-s2.0-S0039610911001514. Retrieved
545 16 January 2024.
546 3. Serra-Burriel M, Keys M, Campillo-Artero C, Agodi A, Barchitta M, Gikas A, Palos C,
547 López-Casasnovas G. 2020. Impact of multi-drug resistant bacteria on economic and
548 clinical outcomes of healthcare-associated infections in adults: Systematic review and
549 meta-analysis. PLOS ONE 15:e0227139.
550 4. Ahmad S, Alfouzan W. 2021. Candida auris: Epidemiology, Diagnosis, Pathogenesis,
551 Antifungal Susceptibility, and Infection Control Measures to Combat the Spread of
552 Infections in Healthcare Facilities. Microorganisms 9:807.
553 5. Benedict K, Forsberg K, Gold JAW, Baggs J, Lyman M. Candida auris–Associated
554 Hospitalizations, United States, 2017–2022 - Volume 29, Number 7—July 2023 - Emerging
555 Infectious Diseases journal - CDC https://doi.org/10.3201/eid2907.230540.
556 6. Lone SA, Ahmad A. 2019. Candida auris—the growing menace to global health. Mycoses
557 62:620–637.
558 7. 2023. Surveillance for Candida auris | Candida auris | Fungal Diseases | CDC.
559 https://www.cdc.gov/fungal/candida-auris/c-auris-surveillance.html. Retrieved 17 January
560 2024.
561 8. Sengupta S, Marimuthu K, Stewardson A, Harbarth S, Durante A, Singh S. 2020.
562 Challenges in Identification of Candida auris in Hospital Laboratories: Comparison
563 Between HIC and LMIC. Infect Control Hosp Epidemiol 41:s158–s158.

564 9. Piedrahita CT, Cadnum JL, Jencson AL, Shaikh AA, Ghannoum MA, Donskey CJ. 2017.
565 Environmental Surfaces in Healthcare Facilities are a Potential Source for Transmission of
566 Candida auris and Other Candida Species. Infect Control Hosp Epidemiol 38:1107–1109.
567 10. Welsh RM, Bentz ML, Shams A, Houston H, Lyons A, Rose LJ, Litvintseva AP. 2017.
568 Survival, Persistence, and Isolation of the Emerging Multidrug-Resistant Pathogenic Yeast
569 Candida auris on a Plastic Health Care Surface. J Clin Microbiol 55:2996–3005.
570 11. US EPA O. 2020. List P: Antimicrobial Products Registered with EPA for Claims Against
571 Candida Auris. Overviews and Factsheets. https://www.epa.gov/pesticide-registration/list-
572 p-antimicrobial-products-registered-epa-claims-against-candida-auris. Retrieved 25
573 January 2024.
574 12. Karmarkar EN, O'Donnell K, Prestel C, Forsberg K, Gade L, Jain S, Schan D, Chow N,
575 McDermott D, Rossow J, Toda M, Ruiz R, Hun S, Dale JL, Gross A, Maruca T, Glowicz J,
576 Brooks R, Bagheri H, Nelson T, Gualandi N, Khwaja Z, Horwich-Scholefield S, Jacobs J,
577 Cheung M, Walters M, Jacobs-Slifka K, Stone ND, Mikhail L, Chaturvedi S, Klein L,
578 Vagnone PS, Schneider E, Berkow EL, Jackson BR, Vallabhaneni S, Zahn M, Epson E.
579 2021. Rapid Assessment and Containment of Candida auris Transmission in Postacute
580 Care Settings—Orange County, California, 2019. Ann Intern Med 174:1554–1562.
581 13. 2023. Tracking Candida auris | Candida auris | Fungal Diseases | CDC.
582 https://www.cdc.gov/fungal/candida-auris/tracking-c-auris.html. Retrieved 17 January
583 2024.
584 14. Worsening Spread of Candida auris in the United States, 2019 to 2021 | Annals of Internal
585 Medicine. https://www.acpjournals.org/doi/full/10.7326/M22-3469. Retrieved 17 January
586 2024.
587 15. Boehm AB, Hughes B, Doung D, Chan-Herur V, Buchman A, Wolfe MK, White BJ. 2022.
588 Wastewater surveillance of human influenza, metapneumovirus, parainfluenza, respiratory
589 syncytial virus (RSV), rhinovirus, and seasonal coronaviruses during the COVID-19

590 pandemic. preprint. Infectious Diseases (except HIV/AIDS).
591 16. Peccia J, Zulli A, Brackney DE, Grubaugh ND, Kaplan EH, Casanovas-Massana A, Ko AI,
592 Malik AA, Wang D, Wang M, Warren JL, Weinberger DM, Arnold W, Omer SB. 2020.
593 Measurement of SARS-CoV-2 RNA in wastewater tracks community infection dynamics.
594 Nat Biotechnol 38:1164–1167.
595 17. Wolfe MK, Paulos AH, Zulli A, Duong D, Shelden B, White BJ, Boehm AB. 2024.
596 Wastewater Detection of Emerging Arbovirus Infections: Case Study of Dengue in the
597 United States. Environ Sci Technol Lett 11:9–15.
598 18. Pacilli M, Kerins JL, Clegg WJ, Walblay KA, Adil H, Kemble SK, Xydis S, McPherson TD,
599 Lin MY, Hayden MK, Froilan MC, Soda E, Tang AS, Valley A, Forsberg K, Gable P,
600 Moulton-Meissner H, Sexton DJ, Jacobs Slifka KM, Vallabhaneni S, Walters MS, Black
601 SR. 2020. Regional Emergence of Candida auris in Chicago and Lessons Learned From
602 Intensive Follow-up at 1 Ventilator-Capable Skilled Nursing Facility. Clin Infect Dis
603 71:e718–e725.
604 19. Babler K, Sharkey M, Arenas S, Amirali A, Beaver C, Comerford S, Goodman K, Grills G,
605 Holung M, Kobetz E, Laine J, Lamar W, Mason C, Pronty D, Reding B, Schürer S,
606 Schaefer Solle N, Stevenson M, Vidović D, Solo-Gabriele H, Shukla B. 2023. Detection of
607 the clinically persistent, pathogenic yeast spp. Candida auris from hospital and municipal
608 wastewater in Miami-Dade County, Florida. Sci Total Environ 898:165459.
609 20. 2023. Infection Prevention and Control for Candida auris | Candida auris | Fungal
610 Diseases | CDC. https://www.cdc.gov/fungal/candida-auris/c-auris-infection-control.html.
611 Retrieved 25 January 2024.
612 21. Kordalewska M, Zhao Y, Lockhart SR, Chowdhary A, Berrio I, Perlin DS. 2017. Rapid and
613 Accurate Molecular Identification of the Emerging Multidrug-Resistant Pathogen Candida
614 auris. J Clin Microbiol 55:2445–2452.
615 22. BLAST: Basic Local Alignment Search Tool. https://blast.ncbi.nlm.nih.gov/Blast.cgi.

616 Retrieved 29 February 2024.
617 23. National Notifiable Diseases Surveillance System (NNDSS) - Healthy People 2030 |
618 health.gov. https://health.gov/healthypeople/objectives-and-data/data-sources-and-
619 methods/data-sources/national-notifiable-diseases-surveillance-system-nndss. Retrieved
620 26 January 2024.
621 24. Weston E (CDC/OID/NCIRD). Guidance on classifying STD case reports into MMWR
622 week.
623 25. Barber C, Crank K, Papp K, Innes GK, Schmitz BW, Chavez J, Rossi A, Gerrity D. 2023.
624 Community-Scale Wastewater Surveillance of Candida auris during an Ongoing Outbreak
625 in Southern Nevada. Environ Sci Technol 57:1755–1763.
626 26. Roldan-Hernandez L, Boehm AB. 2023. Adsorption of Respiratory Syncytial Virus,
627 Rhinovirus, SARS-CoV-2, and F+ Bacteriophage MS2 RNA onto Wastewater Solids from
628 Raw Wastewater. Environ Sci Technol 57:13346–13355.
629 27. Boehm A, Wolfe M, Wigginton K, Bidwell A, White B, Duong D, Hughes B, Chan-Herur V,
630 Naughton C, Bischel H. 2023. Human viral nucleic acids concentrations in wastewater
631 solids from Central and Coastal California, USA. Boehm Res Group Stanf.
632 28. Human viral nucleic acids concentrations in wastewater solids from Central and Coastal
633 California USA | Scientific Data. https://www-nature-
634 com.stanford.idm.oclc.org/articles/s41597-023-02297-7. Retrieved 14 October 2023.
635 29. McClary-Gutierrez JS, Aanderud ZT, Al-faliti M, Duvallet C, Gonzalez R, Guzman J, Holm
636 RH, Jahne MA, Kantor RS, Katsivelis P, Kuhn KG, Langan LM, Mansfeldt C, McLellan SL,
637 Grijalva LMM, Murnane KS, Naughton CC, Packman AI, Paraskevopoulos S, Radniecki
638 TS, Roman FA, Shrestha A, Stadler LB, Steele JA, Swalla BM, Vikesland P, Wartell B,
639 Wilusz CJ, Wong JCC, Boehm AB, Halden RU, Bibby K, Vela JD. 2021. Standardizing
640 data reporting in the research community to enhance the utility of open data for SARS-
641 CoV-2 wastewater surveillance. Environ Sci Water Res Technol 7:1545–1551.

642 30. Rosario K, Symonds EM, Sinigalliano C, Stewart J, Breitbart M. 2009. Pepper mild mottle
643 virus as an indicator of fecal pollution. Appl Environ Microbiol 75:7261–7267.
644 31. U.S. Census Bureau. S0101: Age and Sex - Census Bureau Table. Am Community Surv
645 ACS 1-Year Estim Subj Tables Table S0101.
646 https://data.census.gov/table/ACSST1Y2022.S0101?q=median%20age%20by%20state&g
647 =010XX00US. Retrieved 12 February 2024.
648 32. Nursing Homes. https://hifld-geoplatform.hub.arcgis.com/datasets/geoplatform::nursing-
649 homes/about. Retrieved 13 March 2024.
650 33. Hospitals. https://hifld-geoplatform.hub.arcgis.com/datasets/geoplatform::hospitals/about.
651 Retrieved 13 March 2024.
652 34. USA ZIP Code Boundaries.
653 https://hub.arcgis.com/datasets/d6f7ee6129e241cc9b6f75978e47128b_0/about. Retrieved
654 6 March 2024.
655 35. Efron B. 1979. Bootstrap Methods: Another Look at the Jackknife. Ann Stat 7:1–26.
656 36. DICICCIO T, EFRON B. 1992. More accurate confidence intervals in exponential families.
657 Biometrika 79:231–245.
658 37. Borchardt MA, Boehm AB, Salit M, Spencer SK, Wigginton KR, Noble RT. 2021. The
659 Environmental Microbiology Minimum Information (EMMI) Guidelines: qPCR and dPCR
660 Quality and Reporting for Environmental Microbiology. Environ Sci Technol 55:10210–
661 10223.
662 38. Centers for Disease Control and Prevention (U.S.). 2019. Antibiotic resistance threats in
663 the United States, 2019. Centers for Disease Control and Prevention (U.S.).
664 39. Arenas S, Patel S, Seely SO, Pagan PP, Warde PR, Tamrakar LJ, Parekh DJ, Ferreira T,
665 Zhou Y, Gershengorn HB, Shukla BS. 2023. Operational impact of decreased turnaround
666 times for Candida auris screening tests in a tertiary academic medical center. Antimicrob
667 Steward Healthc Epidemiol ASHE 3:e176.

668 40. Schwartz IS, Dingle TC. 2019. Candida auris. CMAJ Can Med Assoc J 191:E865.
669 41. HIFLD Open. https://hifld-geoplatform.hub.arcgis.com/pages/hifld-open. Retrieved 19
670 March 2024.
671 42. White TC, Esquivel BD, Rouse Salcido EM, Schweiker AM, dos Santos AR, Gade L, Petro
672 E, KuKanich B, KuKanich KS. 2024. Candida auris detected in the oral cavity of a dog in
673 Kansas. mBio 15:e03080-23.
674 43. Yadav A, Wang Y, Jain K, Panwar VAR, Kaur H, Kasana V, Xu J, Chowdhary A. 2023.
675 Candida auris in Dog Ears. J Fungi 9:720.
676 44. Cavalheiro M, Teixeira MC. 2018. Candida Biofilms: Threats, Challenges, and Promising
677 Strategies. Front Med 5:28.
678 45. Nobile CJ, Johnson AD. 2015. Candida albicans Biofilms and Human Disease. Annu Rev
679 Microbiol 69:71–92.
680
681
682
683
684
685
686
687
688